Figures & data
Table 1 Patient demographic and clinical characteristics at baseline
Figure 1A Use of specific treatments during baseline period.
Figure 1B Use of specific treatments during follow-up period.
Table 2 Use of specific treatments during variable-length followup period
Table 3 Treatment use during variable-length follow-up period – incidence ratesTable Footnote*
Table 4 Total health care utilization during baseline and follow-up periods
Table 5 CRPC-specific health care utilization during baseline and follow-up periods
Figure 2A Baseline total health care costs (6-month), mean US$.
Figure 2B Follow-up total health care costs (mean, US$).
Figure 3A Baseline CRPC-specific costs (6-month), mean US$.
Abbreviation: CRPC, castration-resistant prostate cancer.
Figure 3B Follow-up CRPC-specific costs (6-month), mean US$.
Abbreviation: CRPC, castration-resistant prostate cancer.
Table 6 Predicted cumulative total and CRPC-specific health care costs (adjusted)
Appendix Chemotherapy agents included in medication subclasses